Currently, Olaparib is a promising targeted drug as first-line maintenance monotherapy for ovarian cancer, which had a BRCA1/2 mutation 1 and maintenance treatment of platinum-sensitive recurrent ovarian cancer 2. This evidence concerns the gene BRCA1 and ovarian carcinoma.